Sector
HealthcareOpen
₹2,835Prev. Close
₹2,811.7Turnover(Lac.)
₹5,916.29Day's High
₹2,851.6Day's Low
₹2,752.652 Week's High
₹3,653.9552 Week's Low
₹2,201.2Book Value
₹286.76Face Value
₹10Mkt Cap (₹ Cr.)
23,220.11P/E
47.22EPS
59.49Divi. Yield
0.85Dr Lal PathLabs declared a fourth interim dividend of ₹6 per share for 2025, reflecting its strong cash generation and shareholder remittance focus.
The company declared a third interim dividend of ₹6 per share (60% on a face value of ₹10) for FY25.
Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 83.48 | 83.37 | 83.35 | 83.35 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 1,816.18 | 1,606.5 | 1,388.77 | 1,133.74 |
Net Worth | 1,899.66 | 1,689.87 | 1,472.12 | 1,217.09 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Revenue | 1,872.7 | 1,490.55 | 1,273.59 | 1,024.04 |
yoy growth (%) | 25.63 | 17.03 | 24.36 | 16.12 |
Raw materials | -446.31 | -373.9 | -286.86 | -219.31 |
As % of sales | 23.83 | 25.08 | 22.52 | 21.41 |
Employee costs | -320.22 | -257.43 | -232.06 | -175.08 |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Profit before tax | 459.39 | 374.04 | 302.75 | 255.31 |
Depreciation | -75.31 | -69.77 | -68 | -31.04 |
Tax paid | -115.34 | -93.93 | -79.57 | -87.33 |
Working capital | -358.09 | 332.24 | 134.44 | 87.45 |
Other operating items |
Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 25.63 | 17.03 | 24.36 | 16.12 |
Op profit growth | 25.24 | 24.27 | 28.21 | 11.1 |
EBIT growth | 25.47 | 22.51 | 23.92 | 10.42 |
Net profit growth | 22.82 | 25.5 | 32.85 | 10.16 |
Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|---|
Gross Sales | 2,461.4 | 2,226.6 | 2,016.9 | 2,087.4 | 1,581.3 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 2,461.4 | 2,226.6 | 2,016.9 | 2,087.4 | 1,581.3 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 93.4 | 69.2 | 41.7 | 52.5 | 51.3 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Max Healthcare Institute Ltd MAXHEALTH | 1,107.4 | 131.82 | 1,07,645.29 | 138.24 | 0.14 | 697.4 | 81.72 |
Apollo Hospitals Enterprise Ltd APOLLOHOSP | 6,992.5 | 83.66 | 1,00,542.86 | 341.6 | 0.23 | 2,054.8 | 569.62 |
Fortis Healthcare Ltd FORTIS | 667.2 | 250.04 | 50,401.01 | 39.56 | 0.15 | 366.87 | 120.23 |
Narayana Hrudayalaya Ltd NH | 1,775.8 | 84.57 | 36,292.44 | 79.22 | 0.23 | 865.04 | 95.32 |
Global Health Ltd MEDANTA | 1,177.8 | 80.59 | 31,624.82 | 99.31 | 0 | 624.4 | 113.49 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Executive Chairman
Arvind Lal
Whole-time Director
Vandana Lal
Non Executive Director
Archana Lal Erdmann
Non Executive Director
Rahul Sharma
Independent Director
Somya Satsangi
Independent Director
Rohit Bhasin
Independent Director
Arun Duggal
Independent Director
Gurinder Singh Kalra
Independent Director
RAJIT MEHTA
Company Sec. & Compli. Officer
Vinay Gujral
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Dr Lal Pathlabs Ltd
Summary
Dr. Lal PathLabs Limited was incorporated as a Private Limited Company with the name Dr. Lal PathLabs Private Limited, on February 14, 1995 at Delhi. The business of the Partnership Firm, Central Clinical Laboratory was undertaken by the Company. The Company converted into a Public Limited Company and name of the Company was changed to Dr. Lal PathLabs Limited vide fresh Certificate of Incorporation granted by the RoC on August 19, 2015.Dr Lal PathLabs is among the most trusted diagnostic healthcare service provider in India, offering services through over 5000 diagnostic tests and related healthcare services through a nationwide network of medical laboratory centres. Through its integrated, nationwide network, the Company offers patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.Presently, the Company is engaged the business of running laboratories for carrying out pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immunochemistry, immunology, virology, cytology, and other pathological and radiological investigations. The Company has built a national, hub and spoke network that includes its National Reference Laboratory in New Delhi, Regional Reference Lab in Kolkata and 371 other clinical laboratories, 5,102 patient service
Read More
The Dr Lal Pathlabs Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹2777.8 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Dr Lal Pathlabs Ltd is ₹23220.11 Cr. as of 29 Apr ‘25
The PE and PB ratios of Dr Lal Pathlabs Ltd is 47.22 and 11.00 as of 29 Apr ‘25
The 52-week high/low is the highest and lowest price at which a Dr Lal Pathlabs Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Dr Lal Pathlabs Ltd is ₹2201.2 and ₹3653.95 as of 29 Apr ‘25
Dr Lal Pathlabs Ltd's CAGR for 5 Years at 12.00%, 3 Years at 2.23%, 1 Year at 18.36%, 6 Month at -9.08%, 3 Month at 0.68% and 1 Month at 15.77%.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.